HIMS Earnings Rollercoaster and the Options Volatility Sweat

Why It Matters

The swing highlights how earnings guidance and regulatory risk can generate extreme options volatility, creating profit opportunities for savvy traders. It also signals market sensitivity to biotech policy developments.

Key Takeaways

• HIMS beat Q4 earnings but guidance disappointed investors
• Stock fell to $13.75 before rebounding to $15.46
• 25k $16 calls traded at $0.40, indicating bullish bets
• GLP‑1 regulatory scrutiny adds risk to HIMS outlook
• Options community flagged HIMS as top discussion topic

Pulse Analysis

The earnings release from Hims & Hers underscores a familiar pattern in the biotech sector: strong top‑line results can be eclipsed by cautious forward guidance and looming regulatory hurdles. While the company outperformed consensus on revenue and profit metrics, analysts flagged the soft outlook and potential FDA scrutiny of its GLP‑1 offerings as red flags. Such signals often trigger immediate sell pressure, as seen when HIMS slumped to $13.75, reflecting investors’ appetite for risk mitigation in a market that prizes certainty.

Options traders responded to the volatility with a pronounced shift toward bullish positioning. The surge in $16 call volume—approximately 25,000 contracts at a modest $0.40 premium—illustrates a collective bet that the mid‑day rebound will sustain. Simultaneously, the rapid recovery to $15.46 provided relief for put sellers who had been exposed to steep losses. This dynamic illustrates how earnings‑driven price swings can create asymmetric risk‑reward scenarios, prompting traders to calibrate delta exposure and volatility skew to capture upside while hedging downside.

Looking ahead, HIMS’s trajectory will likely be dictated by two forces: the company’s ability to navigate GLP‑1 regulatory pathways and the broader market’s tolerance for earnings‑driven volatility. For institutional investors, the episode serves as a reminder to integrate earnings guidance quality into valuation models, while retail options participants may view the current premium compression as a low‑cost entry point for directional plays. As the ticker remains the top topic within the Options Insider Pro community, continued monitoring of both fundamental updates and options flow will be essential for capitalizing on future price movements.

Original Description

Was it a "hot banger" day on the tape? Not quite—but Hims & Hers ($HIMS) certainly brought the heat. In this clip from the Hot Options Report, Mark Longo dives into the "tale of two tapes" for HIMS. After dropping a Q4 earnings beat last night, the stock was "annihilated" in early Tuesday trading, plunging as low as $13.75 on soft forward guidance and regulatory GLP-1 scrutiny.

Then, the rally kicked in.

We break down the epic mid-day reversal that saw HIMS battle back to $15.46, leaving put-sellers breathing a sigh of relief. We also take a close look at the 25,000 $16 calls expiring this Friday—a massive bet on a continued recovery.

In this clip:

🔹The HIMS Reversal: From a morning bloodbath to a "lift all boats" rally.

🔹Earnings Psychology: Why the "sweaty" trade often ends up being the most profitable.

🔹Call Buying Surge: Analyzing the 40-cent average price on the $16 calls.

🔹Pro Insights: Why HIMS has become the #1 topic for the Options Insider Pro community.

Stay on top of the tape:

Daily Scans & Badges: https://thehotoptionsreport.com

More Options Strategy: https://theoptionsinsider.com